The research team analyzed the effect of using hormone therapy and targeted therapy, in combination, to treat bone tumors in prostate cancer patients. Hormone therapy is a common treatment for prostate cancer. However, it reduces the level of male sex hormones (e.g. testosterone) in the body or prevents them from affecting prostate cancer cells. Abiraterone acetate is a common hormone therapy used often in combination with prednisone, to treat prostate cancer.
In some cases, patients can become resistant to hormone therapy. This means patients will no longer respond to hormone therapy and will require a different treatment approach. In addition, patients can develop metastatic cancer (cancer that spreads out from the primary site) that can affect other organs as well as the bones. Patients with bone tumors require specific targeted treatment (attack the specific site of cancer). A…
